Patient centricity has rapidly gone from a fringe idea to a fundamental principle across the industry, but are pharma companies missing out on more impactful patient engagement through part
George Underwood looks at the rapid growth of patient centricity over the last few years and considers what pharma’s next steps should be to enhance patient engagement.
Developing life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and patients to pharma and industry.
Patient and public involvement (PPI) may be increasingly seen as the “right thing to do”, but without systematic evaluation how do we stop good intentions becoming tick-box tokenism?
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
